Darlifarnib plus cabozantinib in advanced RCC showed 33%-50% objective response rates and a median PFS of 13 months in cabozantinib-naive patients, with a manageable safety profile. The combination outperformed historical benchmarks and supports further development in both naive and TKI-exposed pop…
Darlifarnib combined with cabozantinib in advanced RCC showed objective response rates of 33%-50% and a median PFS of 13 months, with a manageable safety profile. The ongoing phase I-B expansion is randomizing against cabozantinib monotherapy, supporting further development in later-line RCC and po…
– Oral presentation will feature updated data from the FIT-001 Phase 1a study of darlifarnib plus cabozantinib in cabozantinib-naïve, advanced ccRCC patients –– Updated data expected to support darlifarnib’s potential to enhance VEGFR-targeted therapy in ccRCC –– Global randomized Phase 1b study co…
SAN DIEGO, July 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) NASDAQ:KURA, a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on July 1, 2026, the Compensation Committee of the Company’s Board of…
